Partners in Financial Planning Buys Shares of 11,584 Edwards Lifesciences Co. (NYSE:EW)

Partners in Financial Planning purchased a new position in shares of Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 11,584 shares of the medical research company’s stock, valued at approximately $858,000.

Other hedge funds have also recently modified their holdings of the company. Crowley Wealth Management Inc. purchased a new stake in Edwards Lifesciences in the 4th quarter worth approximately $26,000. Millstone Evans Group LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter worth $29,000. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Edwards Lifesciences during the 4th quarter valued at $30,000. Finally, Roble Belko & Company Inc bought a new position in Edwards Lifesciences in the 4th quarter worth $46,000. Institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 400 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the transaction, the vice president now directly owns 22,588 shares in the company, valued at $1,569,414.24. This trade represents a 1.74 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total value of $797,287.50. Following the sale, the chief financial officer now directly owns 30,387 shares of the company’s stock, valued at approximately $2,153,526.69. This trade represents a 27.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 62,553 shares of company stock worth $4,513,064. 1.29% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on EW. Evercore ISI lowered their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research report on Wednesday, February 12th. Canaccord Genuity Group upped their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research note on Thursday, February 13th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price objective for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Piper Sandler upped their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Finally, Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price target for the company from $82.00 to $90.00 in a report on Monday, December 16th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Price Performance

EW stock opened at $70.90 on Monday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.73. The stock has a market cap of $41.68 billion, a PE ratio of 10.17, a P/E/G ratio of 4.82 and a beta of 1.12. The company has a 50-day moving average price of $71.49 and a 200 day moving average price of $70.53.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.